425: Abpro to Go Public via $500 Million SPAC Merger with Atlantic Coastal Acquisition Corp. II

Abpro, a next-generation antibody company, is set to go public through a $500 million business combination with Atlantic Coastal Acquisition Corp. II, aiming to advance its clinical programs and expand its portfolio.

Summary

• Abpro, a next-generation antibody company, is merging with Atlantic Coastal Acquisition Corp. II in a deal valued at $500 million.
• The merger aims to provide Abpro with the capital needed to advance its clinical programs, particularly ABP 102 (in partnership with Celltrion) and ABP 201.
• Abpro's lead molecule, ABP 102, is in late-stage IND enabling studies and is expected to enter Phase 1 trials soon for breast and gastric cancer.
• ABP 201, a bispecific antibody for eyecare indications like Wet AMD and DME, is expected to enter clinical trials next year.
• Abpro has a strategic collaboration with Celltrion, which fully funds the development and manufacturing of ABP 102, with Abpro retaining a 50% profit share.
• Abpro's capital needs for the next two years are estimated to be in the $50 to $75 million range, primarily to fund the development of ABP 201 and ABP 150.
• The company's DiversImmune and MultiMab platforms enable the rapid generation and tailoring of antibodies for various therapeutic applications.
• Health Advances, a consulting company, estimated a $1.2 billion NPV for Abpro's main two compounds.
• Atlantic Coastal II initially sought a target in the mobility space but shifted focus due to the high and non-discretionary capital expenditure requirements in that sector.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Abpro has a promising technology platform, strategic partnerships, and a clear path to clinical development. However, the depressed biotech market and the inherent risks of drug development temper the overall outlook.

Positives

• Abpro has a fully funded partnership with Celltrion for ABP 102, de-risking a significant portion of its clinical development.
• The company's DiversImmune and MultiMab platforms provide a sustainable engine for generating new antibody candidates.
• Abpro has a strong scientific advisory board, including Bob Langer (co-founder of Moderna) and Ron Levy (founder of IDEC/Biogen IDEC).
• The company's capital needs are relatively modest for the next two years, in the $50 to $75 million range.
• Abpro has a 50% profit share with Celltrion for ABP 102.
• The company has a strategic collaboration with Nanjing for China rights to ABP 150, eligible for up to $400 million in milestones.

Negatives

• The biotech market is currently depressed, which could impact the company's ability to raise capital and achieve a favorable valuation.
• The de-SPACing process is expected to be volatile, and the company's valuation may fluctuate significantly.
• ABP 150 and ABP 110 are further off in development.

Risks

• General economic, financial, legal, political and business conditions and changes in domestic and foreign markets could impact the company.
• The outcome of judicial proceedings to which the Company is, or may become a party could impact the company.
• The inability of the parties to enter into definitive agreements or successfully or timely consummate the Proposed Transactions or to satisfy the other conditions to the closing of the Proposed Transactions could impact the company.
• The risk that the approval of the stockholders of ACAB for the Proposed Transactions is not obtained could impact the company.
• Failure to realize the anticipated benefits of the Proposed Transactions, including as a result of a delay in consummating the Proposed Transaction or difficulty in, or costs associated with, integrating the businesses of ACAB and the Company could impact the company.
• The amount of redemption requests made by ACABs stockholders could impact the company.
• The occurrence of events that may give rise to a right of one or both of ACAB and the Company to terminate the Business Combination Agreement could impact the company.
• Risks related to the rollout of the Companys business and the timing of expected business milestones could impact the company.
• The effects of competition on the Companys future business could impact the company.

Future Outlook

Abpro aims to advance its clinical programs, particularly ABP 102 and ABP 201, and expand its portfolio through internal development and potential acquisitions. The company anticipates that the public market conditions will be favorable for biotech companies.

Management Comments

• Ian Chan: 'We feel like we can create a lot of value as time. I know certain parts of the biotech markets are still depressed, but we see an opening right now, and we always believe that good companies with great science will always get funded.'
• Shahraab Ahmad: 'One of the good things about Abpro is that their capital needs are somewhat within their control/discretion. So if market environment gets really hard, I think we have some ability to dial down spending and vice versa.'

Industry Context

The merger reflects a trend of biotech companies seeking funding through SPAC transactions, particularly those with de-risked clinical programs and strategic partnerships. Abpro's focus on bispecific antibodies aligns with the growing interest in targeted immunotherapies in oncology and other disease areas.

Comparison to Industry Standards

• Abpro's approach to eyecare with ABP 201 is similar to Regeneron's Eylea and Roche's Vabysmo, both of which target Wet AMD and DME.
• The company's HER2-positive breast cancer target is similar to Herceptin.
• Abpro's partnership with Celltrion is similar to other biotech companies that have partnered with larger pharmaceutical companies to fund clinical development and commercialization.

Stakeholder Impact

• Shareholders: Potential for value creation through clinical development and commercialization of Abpro's pipeline.
• Employees: Opportunity to work on innovative therapies and contribute to the growth of the company.
• Patients: Potential access to new and improved treatments for cancer, eye diseases, and other conditions.
• Suppliers: Potential for increased business as Abpro's clinical programs advance.
• Creditors: Potential for increased financial stability and repayment capacity.

Next Steps

• Complete the SPAC merger with Atlantic Coastal Acquisition Corp. II.
• Advance ABP 102 into Phase 1 clinical trials.
• Advance ABP 201 into clinical trials.
• Continue development of ABP 150 and ABP 110.
• Potentially pursue acquisitions of technology or companies to expand the platform.

Key Dates